clinical trial · NCT07375355
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
Chronic Myeloid Leukemia in Chronic Phase
brief summary
This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre- and post-treatment, and long-term follow-up data, enabling a comprehensive assessment of asciminib's clinical benefits.
started
Feb 12, 2026
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Apr 1, 2026
official title
Explore the Effectiveness and Safety of Scemblix (Asciminib) for Newly Diagnosed CML-CP Patients in China Real World Setting (ASC4CN)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol